• eTheRNA
  • Combining forces to bring innovative mRNA immunotherapies to the patients


Partnering is a key component of our corporate strategy. eTheRNA is open to exploring innovative ideas – at all stages of development.

eTheRNA focuses on maximizing the value of its proprietary TriMix technology via three routes:

  1. Technology Partnering: eTheRNA intends to build high-value strategic collaborations for exploring the benefits of the TriMix technology in various disease areas
  2. Product Partnering: eTheRNA seeks collaborative partnerships with pharma companies that enable us to develop - and ultimately also to commercialize - differentiated TriMix-based immunotherapies on either a risk-sharing or out-licensing basis
  3. mRNA Production Partnerning: eTheRNA operates a cGMP accredited mRNA production facility in Niel, Belgium. At this stage, available capacity enables eTheRNA to supply mRNA-constructs exclusively for its own development plans, but as its clinical development program advance, the Company has the option to expand capacity, which could present opportunities for strategic partnerships.